Ieq Capital LLC Acquires 504,934 Shares of Boston Scientific Corporation $BSX

Boston Scientific logo with Healthcare background
Image from MarketBeat Media, LLC.

Ieq Capital LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 130.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 892,184 shares of the medical equipment provider's stock after purchasing an additional 504,934 shares during the quarter. Ieq Capital LLC owned about 0.06% of Boston Scientific worth $38,944,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in BSX. BlackRock Inc. acquired a new position in shares of Boston Scientific during the second quarter valued at $5,534,781,000. Primecap Management Co. CA acquired a new stake in shares of Boston Scientific in the 2nd quarter worth about $2,156,233,000. Jupiter Topco LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter worth about $803,357,000. Janus Henderson Group PLC lifted its position in Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. Finally, Amundi lifted its position in Boston Scientific by 1.2% in the 2nd quarter. Amundi now owns 14,296,121 shares of the medical equipment provider's stock valued at $610,158,000 after purchasing an additional 173,208 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on BSX shares. Barclays decreased their target price on shares of Boston Scientific from $48.00 to $45.00 and set an "equal weight" rating for the company in a research report on Friday, October 30th. Argus cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday, July 31st. Oppenheimer downgraded Boston Scientific from an "outperform" rating to a "market perform" rating in a research report on Thursday, October 29th. Evercore decreased their price objective on Boston Scientific from $65.00 to $52.00 and set an "outperform" rating for the company in a report on Wednesday, October 7th. Finally, Mizuho set a $50.00 target price on Boston Scientific in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $61.43.

Check Out Our Latest Report on Boston Scientific

Boston Scientific Stock Performance

Shares of BSX opened at $43.00 on Friday. The firm has a 50-day moving average price of $43.85 and a 200 day moving average price of $53.51. The firm has a market capitalization of $62.33 billion, a PE ratio of 18.22, a P/E/G ratio of 1.29 and a beta of 0.60. The company has a quick ratio of 0.81, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52-week low of $39.57 and a 52-week high of $101.91.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts' consensus estimates of $0.73. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. Boston Scientific's revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Boston Scientific Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

See Also

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Boston Scientific Right Now?

Before you consider Boston Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.

While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines